Cargando…

Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial

BACKGROUND: Keratoconjunctivitis sicca or dry eye disease (DED) is a multifactorial disorder underpinned by a complex inflammatory cycle. Introduction of topical cyclosporine has been a significant advance in the management of DED. In recent years advancements in formulation technology have led to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, A Tarakeswara, Gupta, Amit, Chauhan, Tulika, Basu, Sayan, Batra, Nitin, Sharma, Namrata, Sangwan, Virender S, Gupta, Vinay, Mukherjee, Shoibal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041473/ https://www.ncbi.nlm.nih.gov/pubmed/36973703 http://dx.doi.org/10.1186/s12886-023-02838-z

Ejemplares similares

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
por: Okumus, Seydi, et al.
Publicado: (2012)

Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children
por: Chatterjee, Arkendu, et al.
Publicado: (2019)

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins, Gary W, et al.
Publicado: (2020)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

A New Conception of Keratoconjunctivitis Sicca
Publicado: (1946)

Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates
por: Bayraktutar, Betül N., et al.
Publicado: (2016)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

Changes in tear protein profile in dogs with keratoconjunctivitis sicca following topical treatment using cyclosporine A
por: Sussadee, Metita, et al.
Publicado: (2021)

The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca
por: Gumus, Koray, et al.
Publicado: (2009)

Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
por: Byun, Yong-Soo, et al.
Publicado: (2011)

Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca
por: Williams, David, et al.
Publicado: (2017)

Effect of Oral Choline Alfoscerate on Patients with Keratoconjunctivitis Sicca
por: Choi, Jin Ju, et al.
Publicado: (2020)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
por: Dodi, Pier Luigi
Publicado: (2015)

Differentially Expressed Tear Proteins in Sjögren's Syndrome Keratoconjunctivitis Sicca
por: Yoon, Stephen P., et al.
Publicado: (2023)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery
por: Karadag, Ayse Sevgi, et al.
Publicado: (2021)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee, Michelle K, et al.
Publicado: (2017)

Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits
por: Neves, Magda Luzia, et al.
Publicado: (2013)

Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca
por: Su, Jia-Zeng, et al.
Publicado: (2015)

Differentially Expressed Gene Pathways in the Conjunctiva of Sjögren Syndrome Keratoconjunctivitis Sicca
por: de Paiva, Cintia S., et al.
Publicado: (2021)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
por: Peng, Wenyan, et al.
Publicado: (2022)

Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology
por: Nanavaty, Mayank A., et al.
Publicado: (2014)

Vernal Keratoconjunctivitis spectrum in two generations of a family
por: Singh, Garima, et al.
Publicado: (2020)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study
por: Chen, Minjie, et al.
Publicado: (2021)

Use of Adipose-Derived Mesenchymal Stem Cells in Keratoconjunctivitis Sicca in a Canine Model
por: Villatoro, Antonio J., et al.
Publicado: (2015)

Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca
por: Williams, David L., et al.
Publicado: (2018)

Apricot Kernel Extract and Amygdalin Inhibit Urban Particulate Matter-Induced Keratoconjunctivitis Sicca
por: Hyun, Soo-Wang, et al.
Publicado: (2019)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca
por: Destefanis, Simona, et al.
Publicado: (2016)

Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca
por: Zhang, Xueming, et al.
Publicado: (2018)

Severity of Sjögren’s Syndrome Keratoconjunctivitis Sicca Increases with Increased Percentage of Conjunctival Antigen-Presenting Cells
por: Pflugfelder, Stephen C., et al.
Publicado: (2018)

Topical applications of allogeneic adipose-derived mesenchymal stem cells ameliorate the canine keratoconjunctivitis sicca
por: Wei, Li-Ning, et al.
Publicado: (2022)

Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese
por: Wu, Macy M. S., et al.
Publicado: (2014)

Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation
por: Mullick, Ritika, et al.
Publicado: (2021)

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials
por: Leonardi, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cf3479g5q58b08idllbvaqd2tn